AlloVir Investor Relations Material
Latest events
EGM 2025
AlloVir
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from AlloVir Inc
Access all reports
AlloVir, Inc. is a clinical-stage biotechnology company focused on developing allogeneic, virus-specific T cell (VST) therapies. Its proprietary platform enables the creation of off-the-shelf VSTs designed to prevent and treat severe viral diseases, particularly in patients with compromised immune systems. The company's lead product candidate, posoleucel, targets multiple viruses, including adenovirus, cytomegalovirus, and Epstein-Barr virus. AlloVir's pipeline also includes therapies in development for respiratory and other viral infections. The company is headquartered in Waltham, Massachusetts, and its shares are listed on the NASDAQ.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
ALVR
Country
🇺🇸 United States